Raghava started his career as Alexander von Humboldt (AvH) fellow at Karlsruhe Institute of Technology (KIT), Germany after completing PhD in Organic Chemistry from India in 1994. Since then he has held various senior positions in academia & pharmaceutical industry in Germany and India and worked on several drug discovery projects. Co-inventor of two clinical candidate ASN-001 (NCT02349139) & ASN-007 (NCT 03415126) into first in human clinical Phase I&II trials (NCT02349139) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic KRAS, NRAS & HRAS mutated solid tumors, respectively. Published over 60 research publications, patents, invited review articles, perspectives and book chapters. He is a member of several active chemical societies and reviewer of peer reviewed journals and committees. For his contributions he has received several awards and recognitions. To name few, in 2009, the German Chancellor (Mrs. Angela Merkel) honored him with the German citizenship in recognition for his scientific contributions made in Biotech & Academia to the free state of Saxony, Germany. In 2014, he was selected by the Senate of IIT Kanpur as the youngest member of the International expert panel to review the Chemistry Department of IIT Kanpur, India. In 2017, he is elected as Board of Director for Laxai Life Science. In 2019, he is nominated as Scientific Advisory Board (SAB) member to Tactile Therapeutics Inc. USA.